New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 23, 2013
04:55 EDTGSK, GSK, GSK, IRWD, IRWD, IRWD, PFE, PFE, PFE, MRK, MRK, MRK, REGN, REGN, REGN, LLY, LLY, LLY, BMY, BMY, BMY, ALNY, ALNY, ALNY, LIFE, LIFE, LIFE, BIIB, BIIB, BIIB, AZN, AZN, AZN, SCLN, SCLN, SCLNElsevier Business Intelligence to hold a conference
Pharmaceutical Strategy Conference is being held in New York on September 23-25.
News For GSK;AZN;BIIB;LIFE;ALNY;BMY;LLY;REGN;MRK;PFE;IRWD;SCLN From The Last 14 Days
Check below for free stories on GSK;AZN;BIIB;LIFE;ALNY;BMY;LLY;REGN;MRK;PFE;IRWD;SCLN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 6, 2014
13:57 EDTLLYLilly to present data from bemaciclib as potential treatment for breast cancer
Subscribe for More Information
13:46 EDTPFEPfizer's palbociclib significantly prolonged PFS in metastatic breast cancer
Subscribe for More Information
13:37 EDTMRKMerck presents findings on clinical outcomes following treatment with MK-3475
Subscribe for More Information
April 4, 2014
14:53 EDTSCLNStonepine Capital reports 5.3% passive stake in SciClone
Subscribe for More Information
08:07 EDTMRKMerck, Ferring announce collaboration with WHO
Merck and Ferring Pharmaceuticals announced their collaboration with the World Health Organization to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates. Currently, oxytocin, the standard medicine administered for the prevention of excessive bleeding, is temperature-sensitive and requires sustained cold distribution and storage in hot climates. The WHO will conduct a multi-country clinical study to evaluate the effectiveness of room-temperature-stable carbetocin, as compared to oxytocin. The development of a medicine that can be stored at room temperature has the potential to significantly improve management of bleeding following childbirth in the many areas of the world where cold storage is difficult to achieve and maintain, and thereby help reduce maternal deaths in those areas. Starting this year, the study will take place in 12 countries around the world and enroll approximately 29,000 women. If the results of the study are positive, the organizations will work together with the aim of making the medicine available in developing countries that have a high burden of maternal mortality at an affordable and sustainable public-sector price.
06:29 EDTGSKGlaxoSmithKline cuts China employees amid probe, WSJ reports
According to a source, as it deals with a bribery probe in Beijing, GlaxoSmithKline is cutting employees in China, the Wall Street Journal reports. It is unclear how many of Glaxo's 7,000 employees in China have been let go. Reference Link
April 3, 2014
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:37 EDTGSKAmgen to pay GlaxoSmithKline $275M to terminate denosumab collaboration pact
Subscribe for More Information
09:30 EDTPFEApple, Pfizer others create 'go slow' patent lobby group, Reuters says
Subscribe for More Information
08:51 EDTLLYEli Lilly upgraded at Cowen
As reported previously, Cowen raised its rating on Eli Lilly to Outperform from Neutral. The firm cited its Alimta patent victory, margin expansion potential, and late stage pipeline catalysts for the upgrade. Price target raised to $68 from $61.
08:27 EDTPFE, LLYLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
06:33 EDTLLYEli Lilly upgraded to Outperform from Market Perform at Cowen
Subscribe for More Information
06:28 EDTREGNAtopic dermatitis could bring upside to Regeneron, Celgene, says Citigroup
Citigroup believes Regeneron's (REGN) dupilumab and Celgene's (CELG) Otezla for atopic dermatitis are being overlooked by investors and could provide upside for both names. Citi believes both drugs have good efficacy but adds that dupilumab is more advanced. The firm has a Buy rating on both stocks.
05:50 EDTPFEStocks with implied volatility movement; OXY PFE
Subscribe for More Information
April 2, 2014
11:55 EDTBIIB, PFEUniqure rises after Baxter acquires Chatham Therapeutics
Subscribe for More Information
09:18 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTALNYAlnylam receives positive opinion for orphan drug designation ALN-TTRsc
Alnylam Pharmaceuticals announces that the European Medicines Agency Committee for Orphan Medicinal Products has adopted a positive opinion recommending ALN-TTRsc for designation as an orphan medicinal product for the treatment of transthyretin-mediated amyloidosis. ALN-TTRsc is currently in a pilot Phase 2 clinical trial for the treatment of ATTR patients with TTR cardiac amyloidosis; this study is aimed at evaluating the tolerability of ALN-TTRsc in approximately 15 patients. In addition, the study will assess preliminary clinical activity as measured by knockdown of serum TTR levels and additional exploratory tests, such as cardiac imaging, circulating cardiac biomarkers, 6-minute walk test, New York Heart Association classification, and measures of heart failure symptoms and quality of life. The company expects to present data from the Phase 2 trial in late 2014. Patients completing the Phase 2 trial will be eligible to participate in an open-label extension study for further assessment of general tolerability and clinical activity with long-term dosing; the ALN-TTRsc Phase 2 OLE study is expected to be initiated in mid-2014. Assuming positive results, Alnylam expects to begin a Phase 3 trial in TTR cardiac amyloidosis patients by the end of 2014.
07:44 EDTGSKAgenus down 9.4% after GlaxoSmithKline stops MAGRITi Phase 3 trial
Subscribe for More Information
06:11 EDTGSKGlaxoSmithKline confirms plans to stop MAGRIT Phase III trial
GlaxoSmithKline announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. Data from the trial announced on 20 March 2014 showed that it did not meet its first or second co-primary endpoints as it did not significantly extend disease-free survival when compared to placebo in either the overall MAGE-A3 positive population or in those MAGE-A3-positive patients who did not receive chemotherapy. The trial will be stopped and GSK will now gain access to the un-blinded data, in order to conduct a full assessment of the findings and understand learnings for other aspects of immunotherapy development within GSK. The Independent Data Monitoring Committee indicated that its review of the current safety information revealed no specific safety concern and the data is in line with the known safety information for the MAGE-A3 cancer immunotherapeutic.
05:45 EDTGSKAgenus announces GSK's MAGE-A3 Phase 3 study will be stopped
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use